Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial.
| Revenue (Most Recent Fiscal Year) | $198.77M |
| Net Income (Most Recent Fiscal Year) | $-18.90M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.28 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.51 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -27.63% |
| Net Margin (Trailing 12 Months) | -21.98% |
| Return on Equity (Trailing 12 Months) | -8.30% |
| Return on Assets (Trailing 12 Months) | -6.85% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.93 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.91 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 6.77 |
| Book Value per Share (Most Recent Fiscal Quarter) | $8.68 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.50 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.33 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.75 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 58.93M |
| Free Float | 53.04M |
| Market Capitalization | $258.72M |
| Average Volume (Last 20 Days) | 0.51M |
| Beta (Past 60 Months) | 0.69 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 88.14% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |